+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bacillary Dysentery - Pipeline Review, H2 2019

  • ID: 4858143
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Immuron Ltd
  • LimmaTech Biologics AG
  • Protein Potential LLC
  • MORE
Bacillary Dysentery - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2019, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 2 molecules, respectively.

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Immuron Ltd
  • LimmaTech Biologics AG
  • Protein Potential LLC
  • MORE
Introduction
Report Coverage
Bacillary Dysentery (Shigellosis) - Overview
Bacillary Dysentery (Shigellosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacillary Dysentery (Shigellosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development
Akthelia Pharmaceuticals Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Immuron Ltd
LimmaTech Biologics AG
Protein Potential LLC
Bacillary Dysentery (Shigellosis) - Drug Profiles
(shigella + typhoid) (Bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKT-10081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3536852A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3902986A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF2a-TT15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella [serotype 2a] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella [strain 53G] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Shigetec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacillary Dysentery (Shigellosis) - Dormant Projects
Bacillary Dysentery (Shigellosis) - Product Development Milestones
Featured News & Press Releases
Oct 07, 2019: EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine
Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine
Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact the Publisher
Disclaimer

List of Tables
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by Immuron Ltd, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by LimmaTech Biologics AG, H2 2019
Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential LLC, H2 2019
Bacillary Dysentery (Shigellosis) - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Akthelia Pharmaceuticals Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Immuron Ltd
  • LimmaTech Biologics AG
  • Protein Potential LLC
Note: Product cover images may vary from those shown
Adroll
adroll